Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2019-02-19 Report Publication Anno…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Abivax : Agenda Financier 2019" and explicitly lists future dates for key corporate events, including the 'Publication des Résultats Financiers Annuels 2018' (Annual Financial Results Publication), 'Mise à disposition du Rapport Financier Annuel' (Availability of the Annual Financial Report), and the 'Assemblée Générale annuelle' (Annual General Meeting). This content is a forward-looking schedule of financial and corporate events, not the actual report, results, or meeting materials themselves. Since it announces the timing of future report publications, it fits best under the Report Publication Announcement (RPA) category, which covers announcements regarding the timing or release of company reports. The document length is short (2066 chars), supporting the 'announcement' classification over the actual report.
2019-02-19 French
Abivax veroffentlicht einzigartigen Wirkmechanismus von ABX464 mit entzundungshemmenden und antiviralen Eigenschaften in Nature Scientific Reports
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 28, 2019, announcing the publication of scientific data regarding the company's lead candidate ABX464 in the journal *Nature Scientific Reports*. It details the mechanism of action, quotes the CEO and VP of Research, and discusses future clinical trial plans. This type of announcement, focusing on scientific findings and publication rather than routine financial results (like 10-K or ER) or regulatory voting outcomes, fits best under the general category of scientific or research updates. Since there is no specific code for 'Scientific Publication Announcement', and it is a formal news release about company research, it is classified as a general Regulatory Filing (RNS) as it is disseminated via a news service (DGAP) and does not fit the more specific financial or governance codes. It is not an Earnings Release (ER) as it focuses on R&D, nor an Investor Presentation (IP) as it is a news release about a publication, not the presentation itself.
2019-01-28 German
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces that Abivax has published new data characterizing the mechanism of action of its drug candidate ABX464 in the scientific journal *Nature Scientific Reports*. It contains quotes from the CEO and VP Research, details about the research findings, and contact information for media and investors. This format is characteristic of an initial announcement of scientific or clinical progress, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a press release detailing scientific findings and progress, it does not fit the specific categories like ER, IR, or AR. It is a general corporate announcement regarding research, which often falls under Regulatory Filings (RNS) as a catch-all for non-standard announcements, or potentially Investor Presentation (IP) if it were a slide deck, but here it is a news release about a publication. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a scientific press release that isn't a formal financial report or a specific management/governance update.
2019-01-28 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release from Abivax dated January 28, 2019, announcing the publication of new data regarding the mechanism of action of their drug candidate ABX464 in the scientific journal 'Nature Scientific Reports'. It details scientific findings, quotes the CEO and VP of Research, and provides contact information for press and investors. This type of announcement, which communicates scientific progress, clinical trial updates, and research findings to the public and investors, is best classified as an Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the focus on presenting detailed scientific and clinical progress to support investment interest, 'Investor Presentation' (IP) is a strong fit, as these often include detailed scientific slides or summaries that mirror the content of a presentation, even if released as a press release. Since it is not a formal financial report (10-K, IR, ER) or a formal meeting material (AGM-R, DEF 14A), and it is a detailed communication aimed at investors about the science, IP is the most appropriate category among the choices provided, as it conveys detailed investment-relevant information beyond a simple earnings release or regulatory notice.
2019-01-28 French
Abivax veranstaltet KOL-Event zum Wirkstoffkandidaten ABX464 zur Behandlung von Colitis ulcerosa in Genf
Regulatory Filings Classification · 1% confidence The document is a press release dated January 23, 2019, announcing that the company ABIVAX will host a Key Opinion Leader (KOL) Event on January 30, 2019, in Geneva to discuss clinical data for their drug candidate ABX464 for Ulcerative Colitis. The text details the agenda, speakers (KOL Prof. Ian McGowan and management), and provides webcast information. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about an upcoming investor/expert event, which falls under general corporate communication regarding investor relations and upcoming presentations. Since it is an announcement about an event where presentations will be given, it is best classified as an Investor Presentation (IP) announcement or, more broadly, a Regulatory Filing (RNS) if a more specific category doesn't fit perfectly. However, given the focus on presenting clinical data and strategy to KOLs/investors, 'Investor Presentation' (IP) is a strong candidate, although the document itself is the *announcement* of the event, not the presentation slides. Since the content is about an upcoming presentation/event focused on clinical data and strategy, and it is not a standard financial report, 'Investor Presentation' (IP) is the most contextually relevant category for the subject matter being discussed, even though it is the announcement of the event itself. Given the options, and that it is a specific corporate communication event, I will lean towards IP as the subject matter driver, but acknowledge it is an announcement. If it were purely a miscellaneous regulatory notice, RNS would be used. Since it is specifically about an event where an investor presentation will occur, IP is chosen.
2019-01-23 German
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is a press release announcing a Key Opinion Leader (KOL) event hosted by the company (Abivax) to discuss clinical trial data for a therapeutic candidate (ABX464) in ulcerative colitis. It details the time, location, speakers (KOL and management), and webcast information for the event. This type of announcement, which promotes an upcoming presentation or discussion forum involving management and experts, is best classified as an Investor Presentation (IP) or a general announcement. Since it is an announcement about an event where presentations will be given, and it is not the transcript of the call itself (CT) nor a formal regulatory filing like 10-K or ER, it aligns closely with the nature of an Investor Presentation (IP) which often includes strategic updates and data reviews presented to the investment community. However, given the structure as a 'Press Release' announcing a specific event (KOL event) where management will present data and answer questions, it is a communication aimed at investors and analysts about upcoming material. If the content were the presentation slides themselves, IP would be perfect. As it is the announcement of the event, it is a form of investor communication. Given the options, 'Investor Presentation (IP)' is the closest fit for material detailing clinical data and strategy updates presented to investors, even if this specific document is the invitation/announcement for that presentation. It is not a Call Transcript (CT) as it is a pre-event announcement, nor is it a standard Earnings Release (ER). I will classify it as IP based on the content focus (clinical data, strategy, KOL input).
2019-01-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.